Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma
Abstract To identify risk factors for infection in patients with diffuse large B cell lymphoma (DLBCL) undergoing rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone (R-CHOP) treatment. All patients with DLBCL who received R-CHOP from 2004–2014 in a tertiary Australian hospital wer...
Saved in:
Main Authors: | Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L. Stuart, Tony M. Korman, Karin Thursky, Stephen Opat, Zoe McQuilten |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/8a6a1943b81149ab8bde5882ee1cadd6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma
by: Kirsten Thobe, et al.
Published: (2021) -
Immune targeted therapy for diffuse large B cell lymphoma
by: Yaxin Zheng, et al.
Published: (2021) -
TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Ebru Pekgüç, et al.
Published: (2021) -
Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma
by: Akiko Hashimoto, et al.
Published: (2021) -
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
by: Jiang Xiao, et al.
Published: (2017)